Hospital

Jeff Boyer, PharmD, BCPS, discusses his role in opioid stewardship at the Southern Arizona VA Healthcare System, highlighting his work in pain management coordination, interdisciplinary collaboration, patient and provider education, and data-driven strategies to support safe opioid use and address the opioid crisis.

The findings show robust connections between symptoms, with variations in depression scores directly or indirectly influence fatigue and other symptoms.

Less than 16% of high-risk lung cancer individuals have heard or discussed lung cancer screenings with a health care provider.

The novel therapy demonstrated safety and efficacy in a clinical trial.

About 41% and 30% of patients with chronic spontaneous urticaria (CSU), respectively, achieved well-controlled disease status and complete response when treated with dupilumab.

Throughout a new graduate’s career, that provider status will become mainstream.

ELA026 is a first in class antibody therapy targeting signal regulatory proteins.

Julie Sibbesen, PharmD, discussed strategies to address medical misinformation and educate pharmacists on proper sources of information.

The most commonly reported errors included administering the wrong vaccine or administering an expired vaccine.

Recently announced trial results demonstrate the efficacy of the biologic in multiple disease indications.

It is more important than ever to have pharmacists and pharmacy professionals practicing at the top of their license to assist patients in pharmacy deserts.

Health system pharmacies can enhance operational and financial performance by leveraging key performance indicators, data-driven tools, and automation, ultimately supporting the broader health system’s adaptability and growth within an evolving health care landscape.

Pharmacists play a critical role in treating patients with breast cancer and can help address their social determinant of health challenges.

In children aged 12, 18, and 24 months, there was no association between maternal COVID-19 exposure and abnormal scores on a neurodevelopment screening.

Opioid stewardship coordinator Stephanie Abel, PharmD, BCPS, discusses initiatives such as increasing naloxone access, refining pain management protocols, and addressing stigma around opioid use disorder, highlighting the importance of clear goals and emotional intelligence for effective stewardship programs.

Martha Rumore, PharmD, Esq, discusses the legal and regulatory complexities surrounding tirzepatide compounding following FDA’s removal of the drug from the shortage list, which prompted a lawsuit and led to ongoing uncertainty for 503A and 503B facilities regarding enforcement discretion and future compounding restrictions.

Approximately 15% of patients with polycythemia vera will progress to myelofibrosis.

ASHP investigators determined the severity and impact of ongoing drug shortages, with approximately 99% of respondents reporting that they experienced a shortage.

Intravenous immunoglobulin prescriptions deemed non-compliant according to French national guidelines were more common in younger patients.

Following lung cancer diagnosis, adjusting lifestyle habits can improve treatment responses.

Further efforts may be required to urge eligible members of the public to get screened for lung cancer.

Patients with hereditary angioedema who received sebetralstat earlier had faster complete resolution of their attacks.

Targeted therapies, CDK4/6 inhibitors, and precision medicine are improving outcomes for patients with high-risk and metastatic disease.

Rising cancer rates and costs pose challenges in global oncology markets amid AI and targeted therapy breakthroughs.

Experts from Moffitt Cancer Center discuss the benefit of multidisciplinary teams in lung cancer care.

The 2024 NCODA International Fall Summit took place in Orlando, Florida, from October 23 to October 25.

Findings suggest further need to educate the public on receiving an indicated vaccine as we approach peak respiratory syncytial virus (RSV) season.

The INTerpath-009 trial assessed a combination of V940 with pembrolizumab among individuals with stage II, IIIA, IIIB (N2) non–small cell lung cancer.